Clinical Trials Logo

AMD clinical trials

View clinical trials related to AMD.

Filter by:

NCT ID: NCT01632527 Completed - Clinical trials for Macular Degeneration

Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

Start date: June 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of unilateral subretinal transplantation of HuCNS-SC cells in subjects with geographic atrophy secondary to age-related macular degeneration.

NCT ID: NCT01570790 Completed - Clinical trials for Age-related Macular Degeneration

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

Start date: May 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is assess safety, bioactivity, and maximal tolerated dose of repeated weekly intravenous infusion of combretastatin A-4 phosphate (CA4P) in patients with neovascular age-related macular degeneration

NCT ID: NCT01016873 Completed - Clinical trials for Age-Related Macular Degeneration

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD

INTREPID
Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.

NCT ID: NCT00971464 Completed - AMD Clinical Trials

Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation

AMD
Start date: September 2009
Phase: Phase 2
Study type: Interventional

Patients with advanced Age-Related Macular Degeneration will be randomized into one of two treatment groups. One group will receive eccentric view (EV) training while the other a closed circuit television (CCTV) training for 6 weeks. Reading speed and accuracy will be assessed pre- and post- treatment to determine if one treatment is superior to the other.

NCT ID: NCT00346957 Completed - AMD Clinical Trials

A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

Start date: April 1999
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.

NCT ID: NCT00346866 Completed - AMD Clinical Trials

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

Start date: May 2000
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

NCT ID: NCT00306488 Completed - Clinical trials for Age-Related Macular Degeneration

OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration

Start date: March 2006
Phase: Phase 2
Study type: Interventional

Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop has the potential for chronic treatment of the dry form of age-related macular degeneration. This pilot study of up to 10 eye drop tolerant participants with bilateral geographic atrophy is designed to characterize the effect of 0.45% concentration of OT-551 eye drops given 3 times a day on the progression of geographic atrophy area over a two-year period. Participants will have one eye randomized to receive the eye drop and the fellow eye will be observed only.